ICCC FY 2021 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+25.4% YoY

Gross Profit

$9M45.0% margin

Operating Income

$257,3851.3% margin

Net Income

-$78,292-0.4% margin

EPS (Diluted)

$-0.01

Cash Flow

Operating Cash Flow

$954,170

Free Cash Flow

-$2M

Stock-Based Comp.

$144,313

Balance Sheet

Total Assets

$44M

Total Liabilities

$12M

Stockholders' Equity

$33M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$15M	+25.4%
Gross Profit	$9M	$7M	+26.1%
Operating Income	$257,385	-$1M	+118.7%
Net Income	-$78,292	-$1M	+92.3%